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Abstract
Global vaccine stockpiles, in which vaccines are reserved for use when needed for emergencies or 
supply shortages, have effectively provided countries with the capacity for rapid response to 
emergency situations, such as outbreaks of yellow fever and meningococcal meningitis. The high 
cost and insufficient supply of many vaccines, including oral cholera vaccine and pandemic 
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influenza vaccine, have prompted discussion on expansion of the use of vaccine stockpiles to 
address a wider range of emerging and re-emerging diseases. However, the decision to establish 
and maintain a vaccine stockpile is complex and must take account of disease and vaccine 
characteristics, stockpile management, funding, and ethical concerns, such as equity. Past 
experience with global vaccine stockpiles provide valuable information about the processes for 
their establishment and maintenance. In this Review we explored existing literature and stockpile 
data to discuss the lessons learned and to inform the development of future vaccine stockpiles.
Introduction
Historically, stockpiles have been established to create reserves of commodities ranging 
from weapons, to oil, food, and relief supplies. In public health, global vaccine stockpiles 
have been established for a few selected vaccines, mainly to provide a ready supply in case 
of epidemics. The restricted supply of affordable vaccines has prompted discussions about 
expansion of the number and use of vaccine stockpiles to both alleviate stockouts and 
address a wider range of diseases.1 The result of one such discussion was the decision by 
WHO to establish a global stockpile of oral cholera vaccine for use in epidemic situations, 
as part of an integrated, comprehensive strategy for cholera prevention and control.2 The 
decision to establish this stockpile was complex, and involved factors such as disease 
epidemiology, recommendations for oral cholera vaccine use, the cost and restricted supply 
of vaccine doses available worldwide, and, notably, past experience with other vaccine 
stockpiles. The knowledge gained from the review of these experiences was crucial to 
inform the planning process, and probably resulted in the oral cholera vaccine stockpile 
being made operational more rapidly.
Based on a review of scientific literature and pre sentations on vaccine stockpiles and 
interviews with experts, we describe the general uses and functions of some major global 
vaccine stockpiles, review lessons learned from establishment and maintenance of these 
stockpiles, and examine factors that will aid the development of future stockpiles.
Uses of vaccine stockpiles
A vaccine stockpile can be generally defined as an accumulated supply of vaccines held in 
reserve for use at a later time. This reserve of vaccines might either be a physical stockpile 
held in a discrete location or a virtual stockpile, such as an agreed-upon quantity of vaccine 
set aside by vaccine manufacturers for emergency allocation that can be deployed on 
request. Since vaccine production generally requires substantial lead time, provision of the 
capacity for rapid mobilisation in response to a proven need is a key underlying objective for 
all stockpiles.
Vaccines can be stockpiled for worldwide distribution or maintained by individual countries 
for national use. Uses can involve a range of situations, such as emergency response, disease 
prevention in non-emergent situations, and filling of gaps during supply shortages.3,4 For 
emergency response, vaccine stockpiles can be used to respond to confirmed or predicted 
epidemics at local or regional levels (or both), worldwide pandemics, or bioterrorist threats.5 
Historically, quantities of vaccines for epidemic-prone diseases (eg, yellow fever and 
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meningococcal meningitis) that were not readily available for individual countries, because 
of expense or worldwide supply shortages, have been kept in reserve for distribution to 
targeted areas in response to confirmed emergencies.1,6–8 Other worldwide and national 
stockpiles have been created as precautionary measures for emergency response to either 
predicted major outbreaks or pandemics (eg, highly pathogenic avian influenza A H5N1) or 
feared bioterrorism (eg, smallpox).3,9,10 Vaccine stockpiles can be used for disease 
prevention through provision of supplies for routine immunisation programmes or 
vaccination campaigns.4,7,11 Generally, this purpose is secondary for stockpiles. Vaccine 
supplies which are not used in epidemic situations in a specified time period can be given to 
countries to use in disease prevention programmes, which makes efficient use of the 
vaccines before they expire, such as with yellow fever vaccine.11 Finally, vaccine stockpiles 
can be used to fill gaps during supply shortages.4,12 Stockpiles for this purpose are usually 
established at the national level. The US Pediatric Vaccine Stockpile Program, for example, 
maintains a 6 month supply of routine childhood vaccines in the event of disruptions in 
national vaccine supply.4
Global vaccine stockpiles
Overview
At present, four global vaccine stockpiles are maintained, mainly for emergency response 
situations (table). These include stockpiles of smallpox vaccine, meningococcal vaccine, 
yellow fever and oral cholera vaccines. A fifth global vaccine stockpile—with vaccine doses 
pledged by manufacturers—was recommended for pandemic influenza in 2007, but never 
became operational. In 2013, the WHO Strategic Advisory Group of Experts on 
immunisation concluded that the stockpile should not be established since it was not 
needed.9
Smallpox vaccine stockpile
A previously deadly and endemic disease worldwide, smallpox was declared eradicated in 
1980 by the World Health Assembly.13 This declaration called for the cessation of routine 
smallpox vaccination of children and the maintenance of reserve stocks of smallpox vaccine. 
By 1983, all member nations had ceased routine smallpox vaccination, and some had 
established their own vaccine stockpiles in the event of an outbreak or bioterrorist attack.3,13 
Subsequently, a global stockpile of live-attenuated first, second, and third generation 
smallpox vaccines was created, with donations from WHO member states for use in 
emergency responses, and this stockpile is managed by WHO (table).9 In 2004, the Ad Hoc 
Committee on Orthopoxvirus Infections recommended that the stockpile contain 200 million 
doses of smallpox vaccine, most of which would be held as national stocks until released 
from the donating countries.14 However, in the next year, a simulated bioterrorism exercise 
involving several European and North American cities estimated that smallpox vaccine 
availability in 31 countries and the WHO international stockpile was enough to cover about 
10% of the population worldwide.15 Only eight of the countries involved had sufficient 
supplies to cover 100% of their own populations, which raised the question of who should 
receive a vaccine if an event were to occur. In 2013, the WHO Strategic Advisory Group of 
Experts was asked to provide a recommendation for the size of the stockpile. At that time, 
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the WHO global stockpile contained 2·4 million doses of vaccine maintained in a physical 
stockpile in Switzerland, and 33 million doses kept within donating countries.9 The WHO 
Strategic Advisory Group of Experts reviewed existing data for vaccine availability, 
immunogenicity, effectiveness, and safety, and provided advice on an optimum stockpile 
size.9 The group concluded that, although determination of an optimum size is difficult, the 
estimated 600–700 million doses of smallpox vaccine available through the WHO stockpile 
and national stocks worldwide would be sufficient for response to an epidemic.9 In 
September, 2014, the WHO smallpox vaccine stockpile contained 35 million doses located 
in Switzerland and donating countries (table). No doses have been deployed since the 
establishment of the stockpile.
Meningococcal vaccine stockpile
Meningococcal disease, a leading cause of bacterial meningitis in children and young adults 
worldwide, has an estimated case fatality rate of 5–10%, even when detected early and 
appropriately treated, and can cause substantial and permanent neurological sequelae among 
survivors.16–18 Large scale epidemics occur regularly in the African meningitis belt, which 
spans the continent from Senegal to Ethiopia.18 Several vaccines, including polysaccharide 
and conjugate vaccines, are licensed worldwide, since several serogroups might cause 
epidemic disease in an unpredictable manner. Polysaccharide meningococcal vaccines are 
poorly immunogenic in children younger than 2 years, and provide a relatively short 
duration of protection in children younger than 4 years.19–21 These vaccines are used mainly 
for outbreak response. Conjugate vaccines, which confer long lasting immunity, are used in 
preventive immunisation campaigns, and plans exist for their introduction into routine 
immunisation programmes.
In 1997, an international polysaccharide meningococcal vaccine stockpile was established 
by the International Coordinating Group (ICG) on Vaccine Provision for Epidemic 
Meningitis Control, a partnership between WHO, UNICEF, Médecins Sans Frontières, and 
the International Federation of the Red Cross. This stockpile was created to provide a rapid, 
globally coordinated, emergency response to epidemic disease and initially included about 5 
million doses, bundled with injection materials.6,7 By September 2003, the stockpile 
contained around 6 million doses; the increased volume was partly spurred on by a 2001–02 
W135 meningococcal epidemic in Africa, during which the worldwide supply of the 
appropriate vaccine was inadequate and unaffordable.1 This epidemic also prompted rapid 
development and production of an affordable, trivalent polysaccharide vaccine exclusively 
for the ICG stockpile.1 The rotating stockpile currently contains trivalent and quadrivalent 
polysaccharide and monovalent serogroup A (MenA) conjugate vaccines and is managed by 
the ICG (table).6 Vaccine doses are maintained in a virtual stockpile at the vaccine 
manufacturer sites.
The ICG deploys vaccines as follows (figure). First, a country or non-government 
organisation working within the country must submit a vaccine request and meet the criteria 
for release (ie, evidence of an epidemic situation with laboratory confirmation, preparedness 
to conduct a mass vaccination campaign, and availability of standard storage conditions and 
material resources).22 The ICG secretariat at WHO then circulates this request to UNICEF, 
Yen et al. Page 4
Lancet Infect Dis. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Médecins Sans Frontières, the International Federation of the Red Cross, and WHO 
technical counterparts for assessment, and requests additional information if needed. The 
ICG approves or disapproves the request within 48 h if provided with sufficient information. 
If approved, UNICEF procures vaccines and injection materials and organises delivery of 
vaccines to the country, ideally in 7 days or less after the approval. The ICG decides how to 
manage stocks of polysaccharide vaccine that are nearing expiry. For example, the ICG can 
donate the vaccines for pre-emptive vaccination in at-risk populations. In the case of MenA 
conjugate vaccines not used in epidemic situations during a specified time period, the ICG 
releases the remaining vaccine doses for use in the preventive vaccination campaigns 
planned for that year. Since 1997, more than 50 million doses of vaccines have been given 
to countries for outbreak response, and around 5–15 million vaccine doses are made 
available every year (table).22–26
The emergency vaccine stockpile was financed through ICG appeals to donors in 1997 and 
2002. In 2003, the ICG started a reimbursement request system, by which countries or 
donors were asked to replenish the costs. This system allowed countries facing outbreaks to 
receive vaccines quickly, regardless of their ability to pay, while they raised funds from 
emergency response donors with the support of the ICG agencies. However, since 
reimbursement was not a precondition for vaccine release, actual reimbursement was not 
sufficient to maintain long-term stockpile funding. Since 2009, the meningococcal vaccine 
stockpile has been financed by GAVI, the vaccine alliance and a revolving fund held by 
WHO, by which supplies can be advanced all year round, with later cost replenishment by 
ministries of health, donors, and ICG partners. The revolving fund, which is separate from 
the mechanism used for vaccine procurement by the Pan American Health Organization, 
ensures that the supply of vaccines is sustained should a long-term funding shortage occur,1 
and has proven to be sustainable and effective, since donors whose mandates do not allow 
them to fund preventive mechanisms are willing to contribute to epidemic responses. For the 
2014 meningitis season, the stockpile contained around 7 million doses (WHO, unpublished 
data).
Yellow fever vaccine stockpile
Yellow fever, a mosquito-borne, viral haemorrhagic fever that occurs in tropical South 
America and sub-Saharan Africa, can cause both endemic and epidemic disease. An 
estimated 84 000–170 000 severe cases and 29 000–60 000 deaths caused by yellow fever 
occurred in Africa in 2013.27 In 1988, a joint UNICEF and WHO Technical Group and the 
Expanded Programme on Immunization Global Advisory Group recommended that yellow 
fever vaccine be included in their schedule for countries with endemic yellow fever.8 
However, because of the scarcity of donor funding for vaccine purchasing, only low 
vaccination coverage was achieved, and disease burden remained high in at-risk countries.8 
In 1998, the WHO Technical Consensus Meeting about yellow fever recommended that an 
emergency vaccine stockpile of 1 million doses be created and located with vaccine 
manufacturers in South America and Africa for deployment during epidemics (table).8 The 
stockpile was established in 2001 and contained 2 million doses (WHO, unpublished data).
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The yellow fever vaccine stockpile functions as a rotating stockpile for epidemic response. 
Vaccines not used for epidemic response during a specified time period can be provided to 
at-risk countries for use in disease prevention campaigns.11 In 2003, similar principles to 
those of the ICG on Vaccine Provision for Epidemic Meningitis Control were applied to the 
governance of the yellow fever vaccine stockpile within the Yellow Fever Initiative, 
financed by the GAVI alliance. As such, the ICG for the yellow fever vaccine stockpile 
follows the same vaccine request submission and decision-making process as the 
meningococcal vaccine stockpile; vaccines can be accessed free of charge after meeting the 
ICG criteria for epidemic response.
In 2010, at the recommendation of the ICG and to ensure the sustainability of the yellow 
fever emergency vaccine stockpile, the ICG secretariat established an additional revolving 
fund mechanism for the stockpile, similar to that for the meningococcal vaccine stockpile. 
Since then, the management, governance, and release of vaccines from the stockpile has 
been the same as that described for the meningococcal stockpile (figure).11,22 Between 2001 
and 2013, more than 65 million doses of yellow fever vaccine were distributed, with a yearly 
average of 5 million doses (table). In 2014, the stockpile contained around 6 million doses 
(WHO, unpublished data).
Oral cholera vaccine stockpile
Worldwide, an estimated 1·4–4·3 million cases of cholera and 28 000–142 000 deaths 
caused by cholera occur every year.28 Slow progress in the extension of access to safe water 
and sanitation to underserved populations, limitations of surveillance systems for early 
detection of cholera outbreaks, and scarcity of access to timely and appropriate health care 
have contributed to this burden of disease.2
In May 2011, the World Health Assembly adopted a resolution that calls for the 
implementation of an integrated and comprehensive approach to cholera control, which 
might include use of oral cholera vaccines “where appropriate, in conjunction with other 
recommended prevention and control methods and not as a substitute for such methods”.29 
As part of a response to this resolution, and in the setting of an insufficient worldwide 
supply of cholera vaccine, WHO and partners proposed the establishment of a stockpile of 
inactivated oral cholera vaccine for use in emergency response situations, to help to reduce 
cholera morbidity and mortality in epidemic situations.
In April, 2012, WHO convened a technical working group to address the creation of the oral 
cholera vaccine stockpile and develop a stockpile implementation framework. The working 
group reviewed relevant data and lessons learned from other established vaccine stockpiles 
and made recommendations for the use, management, and monitoring of the stockpile.2 The 
decision was made that the governance structure for this stockpile would be the ICG model 
already used to help countries with the control of epidemic meningococcal meningitis and 
yellow fever. Specific criteria for vaccine deployment, vaccine supply, and funding 
mechanisms were discussed.2 In view of the insufficient supply of the vaccine, an initial 
stockpile size of 2 million doses was recommended, to be stored at vaccine manufacturer 
sites, with a total of 6 million doses to be made available over a 3 year period. Initial 
investments were placed in a revolving fund to guarantee sustainability, and monitoring and 
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assessment of operations will occur regularly to ensure improvements are made as the 
stockpile mechanism evolves. As of September, 2014, 1·5 million doses (WHO, unpublished 
data) have been deployed to respond to emergencies (table).
Pandemic influenza vaccine stockpile
Influenza viruses cause seasonal disease and have the potential to cause pandemic disease. 
The main purpose of a pandemic influenza vaccine stockpile is to provide inactivated and 
live-attenuated vaccines for emergency response, and to delay or prevent pandemic spread 
of a specific influenza strain. However, stockpiling of vaccines for use in either seasonal or 
pandemic influenza is generally not feasible because of seasonal changes in circulating 
viruses and the inability to predict which pandemic virus will emerge. The only possible 
exception is the highly pathogenic avian influenza A H5N1 virus, which continues to cause 
infections in human beings and retains the potential to cause high mortality if it were to 
become a pandemic virus. In May, 2007, the World Health Assembly recommended that a 
highly pathogenic avian influenza A H5N1 vaccine stockpile be established for emergency 
response.10 Later, in November that year, the WHO Strategic Advisory Group of Experts 
recommended that this stockpile include 150 million doses of influenza A H5N1 vaccine for 
use in the context of rapid response and pandemic preparedness.30 In line with these 
recommendations, vaccine manufacturers agreed to pledge up to 110 million doses of 
influenza A H5N1 vaccine to an international stockpile, with doses to be held at vaccine 
manufacturer sites.31 The ensuing discussions outlined issues related to vaccine 
manufacturing capacity, vaccine quality, efficacy and safety, regulatory pathways, ethical 
distribution, liability, and operationalisation and maintenance of the stockpile, in addition to 
vaccine access and risk manage ment.32 In 2009, the influenza A H1N1 pandemic occurred, 
which showed the complexities involved in selection of an influenza strain for the vaccine 
stockpile. With a view to increase equity of access to supplies of influenza A H1N1 
pandemic vaccine to countries without access, WHO initiated the A H1N1 pandemic 
vaccine deployment programme with donated vaccines from manufacturers and countries. 
For this programme, vaccine manu facturers that had pledged influenza A H5N1 vaccine 
agreed to convert their pledges to influenza A H1N1 pandemic vaccine for deployment by 
WHO.33 Influenza A H1N1 vaccine reserves not later deployed by WHO were reconverted 
to pledges of influenza A H5N1 vaccines (or other future pandemic vaccines).
In May 2011, the Pandemic Influenza Preparedness Framework was adopted by WHO to 
improve pandemic preparedness and response, through the sharing of influenza viruses with 
human pandemic potential and improved access to vaccines and other benefits.33 
Subsequently, in November, 2013, the WHO Strategic Advisory Group of Experts agreed 
that, in the setting of relatively stable influenza A H5N1 epidemiology and with the risk of 
poor antigen or strain match between an actual pandemic virus and stockpiled influenza A 
H5N1 vaccine, WHO should not establish a stockpile of A H5N1 vaccine.9 This decision 
was made because of the adoption of the Pandemic Influenza Preparedness Framework, and 
based on the recognition that it would secure real-time access to predictable percentages of 
pandemic influenza vaccines at the time of a pandemic. Therefore, the stockpile never 
became operational.
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Factors to consider in stockpile development
Overview
An actual vaccine stockpile is one element of the complex process involved in the 
surveillance, risk assessment, logistics, interventions, and monitoring and assessment of any 
vaccination campaign.34 An ideal vaccine stockpile would have guaranteed long-term 
funding and would include immediately accessible, inexpensive vaccines that are highly 
effective, safe, easy to administer, thermostable with a long shelf life, and available for all 
target populations. However, this ideal is not feasible under real-world conditions. 
Therefore, based on these considerations and lessons learned from global vaccine stockpiles, 
several factors should be thought of in the determination of whether to establish, and how to 
maintain, a vaccine stockpile (panel). These factors are related to the disease, the vaccine 
type, the management of the stockpile, and ethical considerations.
The disease
Characteristics of the disease—Characteristics of the disease in question, such as the 
epidemic potential or endemicity, seasonality, and geographical distribution (eg, worldwide 
vs regional), will help to establish the mechanism of vaccine distribution, the maintenance 
and physical location of the stockpile, and the target population for vaccination. Some 
disease characteristics might add complexity to decisions about stockpile development. For 
example, antigenic drift and shift in influenza strain predominance make determination of 
whether a strain-specific vaccine stockpile will be useful for an emergency response 
difficult.9 In the case of the influenza A H1N1 pandemic, a stockpile of highly pathogenic 
avian influenza A H5N1 vaccine would not have been useful in an emergency response to 
the pandemic.
Panel: Factors for establishment of a vaccine stockpile
Vaccine preventable diseases
Characteristics of the disease
• What is the epidemiology of the disease?
• What is the geographical distribution of the disease and which countries are at 
risk?
Capacity to detect the disease
• What type of surveillance exists for the disease?
Prevention and treatment of the disease
• Are other preventive or treatment interventions available?
The vaccine
Characteristics of the vaccine
• How effective are the vaccines?
• How quickly can vaccination provide protection against disease?
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• In what formulation is the vaccine available and how is it administered?
• How safe is the vaccine?
• What is this dosing schedule?
• What is the shelf life of the vaccine?
• Is the vaccine WHO-prequalified or licensed within the country receiving it?
Capacity for vaccine production
• How many manufacturers are there for the vaccine?
• How many vaccine doses are available?
• What is the production capacity of the vaccine manufacturers?
Management of the stockpile
Funding
• Who will fund the stockpile in the short-term and long-term?
Forecasting need for vaccines
• How many doses should the stockpile contain?
• What is the contingency plan for the occurrence of a vaccine shortage?
• Is the vaccine used routinely in national immunisation programmes or 
preventive mass vaccination campaigns?
Criteria for release of vaccines
• What epidemiological criteria are needed for release of vaccine doses?
• Who is involved in the decision-making process for release of vaccine?
• What is the plan for vaccine procurement and shipment?
• What is the plan for vaccination?
• What is the plan for storage of additional vaccine doses and related supplies?
Monitoring and evaluation
• What is the plan for monitoring and evaluation of the stockpile.
Ethical considerations
• If the number of vaccine doses is insufficient, who will be prioritised to receive 
the vaccine?
Capacity to detect the disease—For effective use of a vaccine stockpile, surveillance 
systems must have the capacity to rapidly detect an increase in the disease and, in an 
emergency response, establish whether the intervention threshold for vaccine release has 
been reached. Therefore, a sensitive surveillance system allows for timely delivery of 
vaccines and appropriate vaccine selection, as with meningococcal vaccines, which results 
in improved disease prevention.35
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Prevention and treatment of the disease—A vaccine stockpile should be established 
with knowledge of other preventive and treatment interventions for the disease. Thought 
must be given to whether and how vaccination can complement, not replace, life-saving 
interventions. For example, cholera treatment centres, appropriate treatment protocols, and 
plans to improve access to safe water and sanitation should be in place during a cholera 
epidemic, despite the existence of a cholera vaccination campaign.2
The vaccine
Characteristics of the vaccine—Vaccine characteristics help to establish whether the 
vaccine will be useful in a stockpile and how it can be administered effectively. Vaccine 
efficacy and effectiveness can confirm the usefulness of vaccination and identify the target 
populations for vaccination. Vaccine formulation, administration, and storage requirements 
all affect the feasibility of vaccine use in specific settings, and the dosing schedule will help 
to forecast the number of doses needed for the stockpile and vaccination campaigns.5 The 
safety profile and contraindications to vaccination should be noted, to prevent harm to 
individuals, and issues of liability for adverse events after immunisation should be 
addressed, especially in the context of donated vaccines. For example, during discussions 
regarding the deployment of the influenza A H1N1 pandemic influenza vaccine, vaccine 
manu facturers wanted assurance that they would not be liable for adverse events that occur 
during an emergency response for which they had donated vaccines, which were outside 
their control.36 However, they did agree to accept liability for events that were within their 
control, such as compliance with good manufacturing practices.36
Regulatory issues must also be thought of for all stockpiled vaccines, especially if a vaccine 
has not been prequalified by WHO. WHO prequalification is a procedure that assesses the 
quality of vaccines for purchase by UN agencies.37 Prequalification status can help to fast-
track licensing and importation of vaccines not licensed in a receiving country where the 
absence of licensure can result in hesitancy to use a potentially lifesaving vaccine during a 
public health emergency. For example, most available smallpox vaccines are either no 
longer licensed (first generation vaccines) or not widely licensed (second and third 
generation vaccines)9 and this might be a barrier to vaccine acceptance in the event of an 
epidemic. WHO is working to establish comprehensive fast-track regulatory pathways and 
emergency options within the WHO prequalification processes to provide provisional 
approvals of unlicensed vaccines during a public health emergency, similar to the approach 
used during the influenza A H1N1 pandemic.36
Capacity for vaccine production—The number and production capacity of vaccine 
manufacturers and the number of available doses will help with planning for stockpile size 
and maintenance, and affect the capacity for increased vaccine dose production should 
demand be greater than anticipated. For example, the initial oral cholera vaccine stockpile 
size of 2 million doses per year was recommended with insufficient vaccine manufacturing 
capacity in mind.38
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Management of the stockpile
Funding—Short-term and long-term plans for funding must be in place to establish and 
maintain the stockpile without interruption. In some cases, public–private partnerships might 
be necessary, as was the case for production of MenA vaccine. In other cases, revolving 
fund mechanisms have allowed sustainability of the vaccine stockpile by providing longer 
term funding for short-term and future epidemic response (WHO, unpublished data). These 
mechanisms give manufacturers improved capacity to plan vaccine production and supply, 
since financing for future procurement is assured. Additionally, different procurement 
mechanisms can ensure main tenance of vaccine supplies. For example, the polysaccharide 
meningococcal vaccine uses two procurement mechanisms: a purchase commitment 
(reserved stockpile, later payment) or an advanced payment (prepaid stockpile) to 
manufacturers to maintain the stockpile (WHO, unpublished). With the reserved stockpile, 
all financial risks are borne by the manufacturers. With the prepaid stockpile, the ICG 
assumes all risks and absorbs financial losses in cases in which expiring vaccine stocks 
result in wastage or donations for preventive vaccination.
Prediction of need for vaccines—Forecasting of vaccine demand can be difficult.39 
Best guesses are based on historic disease burden data and epidemiology, and adjustments 
might be needed as an epidemic evolves. For example, the vaccine shortages that occurred 
in 2000 during an outbreak in Guinea, and in 2001 in an outbreak in Abidjan, Côte d’Ivoire, 
triggered the creation of a 2 million dose yellow fever vaccine stockpile to avoid acute 
supply disruptions.40 Over time, the stockpile has increased to 6 million doses per year 
through support from the GAVI Alliance. Accurate vaccine forecasting and a contingency 
plan for vaccine shortages developed during the establishment of the stockpile, rather than in 
the midst of an emergency response or actual vaccine shortage, will in our view result in 
more efficient stockpile management. Additionally, information on whether the vaccine is 
used in routine immunisation or vaccination campaigns will help to identify how unused 
doses can be used. Routine yellow fever vaccination and preventive vaccination campaigns 
in some countries, for example, permit the use of unused vaccine stockpile doses for 
preventive immunisation.11
Criteria for release of vaccines—Specific criteria for the release of vaccine doses will 
allow for timely, consistent, and transparent distribution of vaccines in emergency 
responses. These criteria include identification of who will decide whether to distribute 
vaccines and who will manage vaccine procurement and shipment, whether a vaccination 
plan has been prepared, and whether this plan includes in-country storage of vaccine doses 
and related supplies. Not only are these components crucial for vaccine deployment, but so 
is their coordination. For example, before the establishment of the ICG meningococcal 
vaccine stockpile coordinated response, some countries bought substantial quantities of 
meningococcal vaccines independently, which made coordination and forecasting of vaccine 
demand difficult (ICG Secretariat communication with partners and manufacturer). This 
independent purchasing resulted in situations in which some countries had insufficient 
vaccine supply to meet epidemic demand, while other countries had to manage expiring 
vaccine stockpiles.41
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WHO has developed a framework to help with the complex decision making required for 
vaccination in humanitarian emergencies.42 Although the implementation of these decisions 
will not always require use of vaccine stockpiles, similar criteria and considerations should 
be thought of regardless of the source of the vaccines.
Monitoring and assessment—A plan for monitoring and assessment of the operations 
of the vaccine stockpile should be discussed at the time that decisions about management of 
the stockpile are being made. Such a process, in conjunction with reporting of findings to all 
stakeholders, can provide information to improve the functionality of the stockpile and 
contribute to the wider body of evidence on vaccination responses and vaccine stockpiles.2
Ethical considerations
Careful assessment of risks and benefits related to disease and vaccination are needed to 
ensure the fairest distribution of vaccines. However, in settings short of resources, equitable 
distribution of vaccines might not happen. Allocation of vaccines might occur, for example, 
in specific countries or population groups (eg, age or occupational groups), especially if the 
goal is to maximise the benefits of vaccination to contain an outbreak and reduce 
mortality.43 Transparency in the decision-making process for vaccine allocation is crucial to 
ensure trust and confidence in the stockpile mechanism, since complex ethical, political, and 
logistical issues might arise. Such issues were discussed for the oral cholera vaccine 
stockpile.2 In view of the insufficient worldwide supply of cholera vaccines, difficult 
decisions will have to be made about who will receive the cholera vaccine through the 
stockpile, with the equity and utility of vaccination taken into account.
Search strategy and selection criteria
We identified references for this Review through searches of the following sources: 
PubMed articles published from Jan 1, 1946 to Aug 31, 2014, using the terms 
“stockpile”, “vaccine stockpile”, “yellow fever stockpile”, “meningitis stockpile”, 
“meningococcal vaccine stockpile”, “influenza stockpile”, “smallpox stockpile”, 
“Strategic National Stockpile”, and “Pediatric Vaccine Stockpile Program”; publicly 
available presentations regarding specific vaccine stockpiles; grey published by WHO; 
and information publicly available on the GAVI Alliance, PATH, UNICEF, US Centers 
for Disease Control and Prevention, and WHO websites as of Aug 31, 2014. We 
reviewed articles and presentations from these searches and relevant references cited in 
those articles. We only included articles published in English.
Conclusion
Vaccine stockpiles have been part of the response to vaccine-preventable disease outbreaks 
for several decades, and opportunities for their use are likely to increase.42 This Review 
provides a general overview of the complexity involved in the decision to establish and 
maintain a vaccine stockpile, and how the process needs to take account of disease and 
vaccine characteristics, stockpile management, funding, and ethical issues regarding access 
to vaccines. Additional in-depth assessments of the operations of each stockpile could 
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provide further insights into the strengthening of the effectiveness, efficiency, and effect of 
these important resources. Beyond provision of a crucial supply to respond to vaccine-
preventable disease outbreaks, creation of stockpiles can drive innovations for the 
development of vaccines with longer shelf lives, increased efficacy, and more efficient 
delivery. Proposed stockpiles, such as those for oral polio vaccine—and inactivated polio 
vaccine for the post-oral-polio vaccine era—underscore the complexity and opportunities 
that such reserves can provide.43 Although lessons learned from establishment and 
maintenance of existing vaccine stockpiles can help to inform policy, each new vaccine 
stockpile will probably face additional challenges and costs.
Acknowledgments
We thank Nancy Messonnier and Inger Damon (US Centers for Disease Control and Prevention) for their expertise 
and review of this manuscript. We also thank David Wood (WHO) for his advice on regulatory and liability issues 
and Stephen Martin (WHO) for his coordination of initial discussions among the coauthors.
References
1. Nelson CB, Birmingham M, Costa A, et al. Preparedness for infectious threats: public-private 
partnership to develop an affordable vaccine for an emergent threat: the trivalent Neisseria 
meningitidis ACW135 polysaccharide vaccine. Am J Public Health. 2007; 97(suppl 1):S15–22. 
[PubMed: 17413077] 
2. WHO. WHO Technical Working Group on creation of an oral cholera vaccine stockpile: meeting 
report. Geneva: World Health Organization; 2012. 
3. Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect Dis. 2005; 5:647–52. [PubMed: 
16183519] 
4. Lane KS, Chu SY, Santoli JM. The United States pediatric vaccine stockpile program. Clin Infect 
Dis. 2006; 42(suppl 3):S125–29. [PubMed: 16447134] 
5. Milstien J, Lambert S. Emergency response vaccines--a challenge for the public sector and the 
vaccine industry. Vaccine. 2002; 21:146–54. [PubMed: 12443673] 
6. Costa, A. Yellow fever and meningococcal vaccine stockpiles. Oral cholera vaccine stockpile 
meeting; Geneva, Switzerland. 2011; 
7. WHO. Response to epidemic meningitis in Africa, 1997. Wkly Epidemiol Rec. 1997; 72:313–18. 
[PubMed: 9347699] 
8. WHO. Yellow fever—technical consensus meeting; Geneva. 2–3 March 1998; Geneva: World 
Health Organization; 1998. 
9. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013–
conclusions and recommendations. Wkly Epidemiol Rec. 2014; 89:1–20. [PubMed: 24466571] 
10. World Health Assembly. Resolution 60.28 - Pandemic influenza preparedness: sharing of influenza 
viruses and access to vaccines and other benefits. Resolutions and decisions; Sixtieth World 
Health Assembly; Geneva. 14–23 May 2007; Geneva: World Health Organization; 2007. 
11. WHO, UNICEF. Yellow Fever Initiative: providing an opportunity of a lifetime. Geneva: World 
Health Organization; 2010. http://www.who.int/csr/disease/yellowfev/YFIbrochure.pdf?ua=1 
[accessed Oct 13, 2011]
12. Klein JO, Myers MG. Vaccine shortages: why they occur and what needs to be done to strengthen 
vaccine supply. Pediatrics. 2006; 117:2269–75. [PubMed: 16740872] 
13. WHO. The global eradication of smallpox: final report of the Global Commission for the 
Certification of Smallpox Eradication. Geneva: World Health Organization; 1979. 
14. WHO. Report of the meeting of the ad hoc committee on orthopoxvirus infections; Geneva, 
Switzerland. 31 August–1 September 2004; Geneva: World Health Organization; 2004. 
15. Smith BT, Inglesby TV, Brimmer E, et al. Navigating the storm: report and recommendations from 
the Atlantic Storm exercise. Biosecur Bioterror. 2005; 3:256–67. [PubMed: 16181048] 
Yen et al. Page 13
Lancet Infect Dis. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
16. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to 
bacterial meningitis among African children: a systematic literature review. BMC Med. 2009; 
7:47. [PubMed: 19751516] 
17. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and 
Neisseria meningitidis. Lancet. 2007; 369:2196–210. [PubMed: 17604802] 
18. WHO. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 
2011; 86:521–39. [PubMed: 22128384] 
19. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 
1999; 93:341–53. [PubMed: 10674069] 
20. Käyhty H, Karanko V, Peltola H, Sarna S, Mäkelä PH. Serum antibodies to capsular 
polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and 
children. J Infect Dis. 1980; 142:861–68. [PubMed: 6780634] 
21. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical 
protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985; 2:114–
18. [PubMed: 2862316] 
22. International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control. 
Guidelines for applying to the emergency stockpile. Geneva: World Health Organization; 2008. 
23. Fernandez, KA.; Costa, A. Building partnerships to improve outbreak preparedness: the 
establishment of an emergency vaccine stockpile for meningitis epidemics. International 
Conference on Emerging Infectious Diseases; Atlanta, GA, USA. March 16–19, 2008; Board 46
24. WHO. Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec. 2010; 
85:47–63. [PubMed: 20210043] 
25. WHO. Meningitis in Burkina Faso, Chad, Niger, Nigeria and Ghana: 2010 epidemic season. Wkly 
Epidemiol Rec. 2011; 86:143–51. [PubMed: 21476333] 
26. WHO. Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs 
and future perspectives. Wkly Epidemiol Rec. 2013; 88:129–36. [PubMed: 23544241] 
27. WHO. Vaccines and vaccination against yellow fever. WHO position paper–June 2013. Wkly 
Epidemiol Rec. 2013; 88:269–83. [PubMed: 23909008] 
28. Ali M, Lopez AL, You YA, et al. The global burden of cholera. Bull World Health Organ. 2012; 
90:209–18. [PubMed: 22461716] 
29. World Health Assembly. Sixty-fourth World Health Assembly. Geneva: World Health 
Organization; 2011. Resolution 64.18 - Cholera: mechanisms for control and prevention. 
30. WHO. Meeting of the Immunization Strategic Advisory Group of Experts, November 2007–
conclusions and recommendations. Wkly Epidemiol Rec. 2008; 83:1–15. [PubMed: 18175408] 
31. WHO. The Global Action Plan to increase supply of pandemic influenza vaccines. Report of the 
second meeting of the Advisory Group; Pune, Maharashtra, India. 26 November 2008; Geneva: 
World Health Organization; 2009. 
32. Miller, E. Report from the SAGE working group on influenza vaccines and immunizations. SAGE 
Meeting; Geneva. July 12–14, 2011; http://www.who.int/influenza_vaccines_plan/resources/
lmiller.pdf
33. WHO. Pandemic influenza preparedness framework for the sharing of influenza viruses and access 
to vaccines and other benefits. Geneva: World Health Organization; 2011. 
34. Briand, S. Some lessons learned from other vaccine stockpiles. Informal Consultation on Technical 
Specifications for a (WHO) International H5N1 Vaccine Stockpile; Geneva. Oct 17–18, 2007; 
http://www.who.int/biologicals/areas/vaccines/influenza/influenza_mtg_17-18_October_2007/en/
index1.html
35. WHO. Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly 
Epidemiol Rec. 2000; 75:306–09. [PubMed: 11045076] 
36. WHO. Report of the WHO pandemic influenza A(H1N1) vaccine deployment initiative. Geneva: 
World Health Organization; 2012. 
37. Dellepiane N, Wood D. Twenty-five years of the WHO vaccines prequalification programme 
(1987–2012): lessons learned and future perspectives. Vaccine. 2013 published online Dec 2. 
10.1016/j.vaccine.2013.11.066
Yen et al. Page 14
Lancet Infect Dis. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
38. Maskery B, DeRoeck D, Levin A, Kim YE, Wierzba TF, Clemens JD. Strategy, demand, 
management, and costs of an international cholera vaccine stockpile. J Infect Dis. 2013; 208(suppl 
1):S15–22. [PubMed: 24101640] 
39. Milstien J. Emergency response vaccines: lessons learned in response to communicable diseases. 
Expert Opin Biol Ther. 2003; 3:1121–31. [PubMed: 14519076] 
40. Nathan N, Barry M, Van Herp M, Zeller H. Shortage of vaccines during a yellow fever outbreak in 
Guinea. Lancet. 2001; 358:2129–30. [PubMed: 11784630] 
41. WHO. Guidance on development and implementation of a national deployment and vaccination 
plan for pandemic influenza vaccines. Geneva: World Health Organization; 2012. 
42. Strategic Advisory Group of Experts on Immunization Working Group on Vaccination in 
Humanitarian Emergencies. Vaccination in acute humanitarian emergencies: a framework for 
decision making. Geneva: World Health Organization; 2013. 
43. Moodley K, Hardie K, Selgelid MJ, et al. Ethical considerations for vaccination programmes in 
acute humanitarian emergencies. Bull World Health Organ. 2013; 91:290–97. [PubMed: 
23599553] 
Yen et al. Page 15
Lancet Infect Dis. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure. Operational steps of the ICG mechanism
MSF=Médecins Sans Frontières. IFRC=International Federation of the Red Cross. ICG= 
International Coordinating Group.
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Table
Overview of existing global vaccine stockpiles
Smallpox vaccine Meningococcal vaccine Yellow fever vaccine Oral cholera vaccine
Year established 1980 1997 2001 2013
Main uses Emergency response Emergency response, 
disease prevention 
(conjugate)
Emergency response, 
disease prevention
Emergency response, 
humanitarian emergencies
Types of vaccine Live-attenuated Polysaccharide (bivalent, 
trivalent, quadrivalent), 
conjugate (monovalent)
Live-attenuated Inactivated
Storage WHO headquarters and 
multiple nations
Manufacturer Manufacturer Manufacturer
Management WHO ICG ICG ICG
Number of doses 
available (annual 
average)
35 million 9 million 5 million 2 million
Number of doses 
distributed to date 
(annual average)
None 4 million 5 million 1·5 million
Funding mechanism Donations, WHO procurement Donations, revolving fund Donations, revolving fund Donations, revolving fund
ICG=International Coordinating Group.
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